Featured Posts
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs, rapid…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
Study
Safety, risk and the precautionary principle: rethinking precautionary approaches to the regulation of transgenic plants
Full Document Available in PDF Ever since completion of the Cartagena Protocol on Biosafety in…
Legal Brief
Memorandum Opinion in Association of Physicians and Surgeons vs US FDA
Comment
Comments Regarding the Constitutionality of FDA Treatment of Product Information
This request for comments represents a welcome departure from FDA’s prior treatment of First Amendment concerns in the context of product advertising, labeling, and promotions.
Study
Hidden Truth: The Perils and Protection of Off-Label Drug and Medical Device Promotion
Full Document Available in PDF What can you do if you learn you have a life-threatening…
News Release
CEI Slams FDA Vote on Avastin
Washington, D.C., June 29, 2011 — An FDA advisory committee voted today to revoke the approval for breast cancer treatment from the drug Avastin.
Citation
Greg Conko on FDA Approval for Avastin
CEI Senior Fellow Greg Conko discusses the FDA's pending decision on whether or not to withdraw its approval of Avastin as a treatment for breast…